4//SEC Filing
Lisicki Robert 4
Accession 0001628280-21-015950
CIK 0001080709other
Filed
Aug 4, 8:00 PM ET
Accepted
Aug 5, 6:08 PM ET
Size
10.7 KB
Accession
0001628280-21-015950
Insider Transaction Report
Form 4
Lisicki Robert
EVP, Chief Commercial Officer
Transactions
- Sale
Common Stock
2021-08-03$59.84/sh−5,605$335,403→ 27,996 total - Exercise/Conversion
Common Stock
2021-08-03$40.95/sh+17,500$716,625→ 33,601 total - Sale
Common Stock
2021-08-03$60.20/sh−11,895$716,079→ 16,101 total - Exercise/Conversion
Employee Stock Option (right to buy)
2021-08-03−17,500→ 110,000 totalExercise: $40.95Exp: 2025-11-26→ Common Stock (17,500 underlying)
Footnotes (4)
- [F1]The transactions reported in this line item of this Form 4 were effected pursuant to a Rule 10b5-1 trading plan established by the reporting person.
- [F2]The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.63 to $59.99, inclusive. The reporting person undertakes to provide Arena Pharmaceuticals, Inc., any security holder of Arena Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2 and 3 to this Form 4.
- [F3]The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.00 to $60.74, inclusive.
- [F4]The options vest over four years, with 25% of the shares subject to the option vesting on November 26, 2019, and the remainder of the shares vesting monthly over the following three years in equal installments (except as otherwise necessary to avoid vesting of a fractional share), and are exercisable once vested.
Documents
Issuer
ARENA PHARMACEUTICALS INC
CIK 0001080709
Entity typeother
Related Parties
1- filerCIK 0001779614
Filing Metadata
- Form type
- 4
- Filed
- Aug 4, 8:00 PM ET
- Accepted
- Aug 5, 6:08 PM ET
- Size
- 10.7 KB